The creation of high-quality, innovative small molecule leads is a continual challenge in drug discovery. Against a background of increasing cost, the rate of drug discovery has remained stagnant for over 60 years. Improving research and development productivity is a considerable obstacle for the pharmaceutical sector. To address these challenges, innovative methods are crucial. Curia addresses this in a novel way through CLC.View resource
More from Curia
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...